Blinatumomab in combination with olverembatinib and concurrent intrathecal chemotherapy successfully treated a chronic myeloid leukemia relapse with central nervous system blast crisis: case report and literature review.
{"title":"Blinatumomab in combination with olverembatinib and concurrent intrathecal chemotherapy successfully treated a chronic myeloid leukemia relapse with central nervous system blast crisis: case report and literature review.","authors":"Ying Wang, Qiong Liu, Chun-Li Xu, Dong-Ping Huang, Yu Chen","doi":"10.1007/s00277-025-06351-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Central nervous system (CNS) blast crisis in chronic myeloid leukemia (CML) is rare and presents a significant treatment challenge due to the limited ability of many systemic therapies to penetrate the blood-brain barrier (BBB). This case highlights the need for effective treatment strategies.</p><p><strong>Case report: </strong>This case report describes a 43-year-old man diagnosed with CML who developed a CNS blast crisis followed by bone marrow relapse while receiving flumatinib.</p><p><strong>Discussion: </strong>The patient achieved complete remission (CR) in both the bone marrow and CNS after receiving a combination of blinatumomab and olverembatinib, along with weekly intrathecal chemotherapy.</p><p><strong>Conclusions: </strong>The combination of blinatumomab, olverembatinib, and concurrent intrathecal chemotherapy may be an effective treatment strategy for CML progression, particularly in cases with CNS involvement.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06351-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Central nervous system (CNS) blast crisis in chronic myeloid leukemia (CML) is rare and presents a significant treatment challenge due to the limited ability of many systemic therapies to penetrate the blood-brain barrier (BBB). This case highlights the need for effective treatment strategies.
Case report: This case report describes a 43-year-old man diagnosed with CML who developed a CNS blast crisis followed by bone marrow relapse while receiving flumatinib.
Discussion: The patient achieved complete remission (CR) in both the bone marrow and CNS after receiving a combination of blinatumomab and olverembatinib, along with weekly intrathecal chemotherapy.
Conclusions: The combination of blinatumomab, olverembatinib, and concurrent intrathecal chemotherapy may be an effective treatment strategy for CML progression, particularly in cases with CNS involvement.
期刊介绍：
Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
